Trial Results for Diabetes Drug Released
Posted on: Monday, 12 June 2006, 18:00 CDT
A U.S. Food and Drug Administration Phase 3 study indicates Glumetza -- a drug to be launched this summer-- improves upon the diabetes drug metformin.
The pharmaceutical company Depomed Inc., makers of Glumetza, said metformin is one of the most common type 2 diabetes drugs, yet 60 percent of patients stop taking it as prescribed within the first year, mainly because of side effects such as nausea and diarrhea.
In the Phase 3 trial, Depomed said Glumetza had 97 percent patient compliance because of its formulation that allows for once-daily dosing, excellent tolerability, and better efficacy at high doses.
The results of the second Phase 3 clinical trial appear in the June issue of the journal Diabetes.
Source: United Press International
Related Articles
- SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise
- PAREXEL Expands Early Phase Drug Development Capabilities With Dedicated Proof of Concept Solutions
- XTL Completes Patient Randomization in Phase IIb Study of Diabetic Pain Drug
- Sangamo Says Diabetic Neuropathy Drug Effective in Phase I
- Gain Insight into the Pipeline Status of Diabetic Nephropathy Drugs By Company and By Stage and Also Get a Summary of the Latest News and Developments in This Area
- Metabolic Endocrinology - Diabetic Neuropathy Drug Pipeline Report - Study the Top 20 Companies With Products in the Early and Late Stage of Development
- Abbott Starts Diabetic Pain Drug Trial
- Use of Sequenom's MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria
- Positive Early Study for Sangamo's Diabetic Neuropathy Drug
- Eli Lilly's Ruboxistaurin Poised to Transform the Diabetic Neuropathy Drug Market
 |
 |
User Comments (0)
RSS Feeds